|
|
Blood, 15 September 2007, Vol. 110, No. 6, pp. 1916-1923.
Prepublished online as a Blood First Edition Paper on May 17, 2007; DOI 10.1182/blood-2007-02-062117.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines
Nia Tatsis1,
Julie C. Fitzgerald1,2,
Arturo Reyes-Sandoval1,3,
Kimberly C. Harris-McCoy1,
Scott E. Hensley1,
Dongming Zhou1,
Shih-Wen Lin1,
Ang Bian1,
Zhi Quan Xiang1,
Amaya Iparraguirre1,
Cesar Lopez-Camacho1,4,
E. John Wherry1, and
Hildegund C. J. Ertl1
1 Wistar Institute, Philadelphia, PA;
2 Children's Hospital of Philadelphia, PA;
3 Oxford University, United Kingdom;
4 Posgrado en Ciencias Quimicas, Instituto de Quimica–, Instituto de Ciencias de la Universidad de Puebla (ICUAP), Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Mexico
CD8+ T cell-numbers rapidly expand and then contract after exposure to their cognate antigen. Here we show that the sustained frequencies of transgene product-specific CD8+ T cells elicited by replication-defective adenovirus vectors are linked to persistence of low levels of transcriptionally active adenovirus vector genomes at the site of inoculation, in liver, and lymphatic tissues. Continuously produced small amounts of antigen maintain fully active effector CD8+ T cells, while also allowing for their differentiation into central memory cells. The long-term persistence of adenoviral vectors may be highly advantageous for their use as vaccines against pathogens for which T-cell–mediated protection requires both fully activated T cells for immediate control of virus-infected cells and central memory CD8+ T cells that, because of their higher proliferative capacity, may be suited best to eliminate cells infected by pathogens that escaped the initial wave of effector T cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. D. Finn, J. Bassett, J. B. Millar, N. Grinshtein, T. C. Yang, R. Parsons, C. Evelegh, Y. Wan, R. J. Parks, and J. L. Bramson
Persistence of Transgene Expression Influences CD8+ T-Cell Expansion and Maintenance following Immunization with Recombinant Adenovirus
J. Virol.,
December 1, 2009;
83(23):
12027 - 12036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Haut and H. C. J. Ertl
Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine
J. Leukoc. Biol.,
October 1, 2009;
86(4):
779 - 793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wang, C. Cheng, S.-Y. Ko, W.-P. Kong, M. Kanekiyo, D. Einfeld, R. M. Schwartz, C. R. King, J. G. D. Gall, and G. J. Nabel
Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity
J. Virol.,
July 15, 2009;
83(14):
7166 - 7175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Tatsis, M. O. Lasaro, S.-W. Lin, Z. Q. Xiang, D. Zhou, L. DiMenna, H. Li, A. Bian, S. Abdulla, Y. Li, et al.
Adenovirus Vector-Induced Immune Responses in Nonhuman Primates: Responses to Prime Boost Regimens
J. Immunol.,
May 15, 2009;
182(10):
6587 - 6599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Li, M. Zhang, C. Zhou, X. Zhao, N. Iijima, and F. R. Frankel
Novel Vaccination Protocol with Two Live Mucosal Vectors Elicits Strong Cell-Mediated Immunity in the Vagina and Protects against Vaginal Virus Challenge
J. Immunol.,
February 15, 2008;
180(4):
2504 - 2513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
